Artivion Inc Dossier
Qualitative Analysis
Business overview
Artivion, Inc. (formerly CryoLife, Inc.) is a leading medical device and tissue processing company specializing in aortic-centric solutions for cardiac and vascular surgeons. The company operates through two primary segments: Medical Devices and Preservation Services. Its comprehensive product portfolio includes aortic stent grafts, On-X mechanical heart valves, surgical sealants (such as BioGlue), and cryopreserved human cardiac and vascular allografts. Artivion focuses on addressing the global medical needs of patients suffering from aortic diseases, leveraging a direct sales force in North America and Europe alongside independent distributors in other international markets.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Consolidating market leadership in the aortic arch repair segment by offering a complete, clinically differentiated suite of solutions consisting of AMDS (Ascyrus Medical Dissection Stent), the newly acquired NEXUS Aortic Arch System, and the ARCEVO LSA system.
Expected impact: Positions Artivion as the only company globally with a complete portfolio of aortic arch solutions, addressing a combined addressable market expansion of over $700 million.
Leveraging positive long-term clinical data demonstrating mortality and reoperation benefits to capture market share from bioprosthetic valves, specifically targeting younger patients (under 65 years of age) in the U.S.
Expected impact: Take further market share in the mechanical heart valve market based on the FDA's approved lower INR indication for the On-X aortic heart valve.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To acquire full ownership of the FDA-approved NEXUS Aortic Arch System and its underlying platform technology, completing Artivion's three-pronged aortic arch portfolio and adding a robust pipeline of next-generation endovascular arch technologies.
Financial impact: Paid an upfront net purchase price of $135 million (funded via a $150 million delayed draw term loan), with up to $200 million in performance-based contingent consideration. It is expected to incur $8 million of incremental expenses in 2026 and be EBITDA neutral in 2027 before contributing to meaningful free cash flow.
Strategic Partnerships
Served as the foundation for Artivion's entry into the endovascular aortic arch repair market, acting as the exclusive distributor of the NEXUS System in EMEA since 2019 and providing the credit facilities that ultimately led to the acquisition option.
Terms: Included distribution rights, previous loans of up to $15 million, and a structured option to acquire the company within 90 days of FDA PMA approval.